GlassScriptPhysician profile
Timothy W Eller
NPI 1700827433
$6,063.91
in general payments reported to CMS, 2019-2025
34 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $133 · 2021: $14.78 · 2022: $256 · 2023: $1,458 · 2024: $1,772 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,793.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $965.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $834.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $765.90 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $692.72 | 2019-2025 | |
| Amgen INC. | $309.50 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Dexcom, INC. | $277.83 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $233.40 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $197.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.52 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $190.21 | 2023-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $178.08 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $175.34 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $171.72 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $131.49 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $103.57 | 2019-2024 | Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $85.48 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $73.50 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $66.02 | 2023-2024 | Austedo Xr, Uzedy |
| Xeris Pharmaceuticals, INC. | $59.59 | 2024-2025 | Gvoke Hypopen |
| Allergan, INC. | $59.05 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $51.13 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $43.53 | 2019 | |
| Radius Health, INC. | $34.05 | 2019-2023 | Tymlos |
| Phathom Pharmaceuticals, INC. | $20.38 | 2025 | Voquezna |
| Shield Therapeutics INC | $17.18 | 2024 | |
| Silk Road Medical, INC. | $17.10 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Avanir Pharmaceuticals, INC. | $16.03 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2024 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $14.98 | 2025 | |
| Ucb, INC. | $14.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2024 | Rexulti |
| Mylan Specialty L.P. | $13.76 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.11 | 2024 | |
| Sumitomo Pharma America, INC. | $11.14 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Eller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.